- NCIt
- C8101
Loading cancer entity…
Loading cancer entity…
Clinical trials
1,164 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03441100 | TCR-engineered T Cells in Solid Tumors: IMA202-101(ACTengine) | completed | Phase 1 | 16 | Immatics US, Inc.INDUSTRY | 2 | Feb 4, 2025 | clinicaltrials |
| NCT03628677 | A Study to Evaluate the Safety and Tolerability of AB154 in Participants With Advanced Malignancies | completed | Phase 1 | 75 | Arcus Biosciences, Inc.INDUSTRY | 2 | Feb 4, 2025 | clinicaltrials |
| NCT05662397 | A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody | active not recruiting | Phase 1 / Phase 2 | 77 | HotSpot Therapeutics, IncINDUSTRY | 3 | Feb 4, 2025 | clinicaltrials |
| NCT05601219 | A Phase 1 Study of ADA-011 for Subjects With Advanced Solid Tumors | terminated | Phase 1 | 46 | Adanate, IncINDUSTRY | 1 | Jan 28, 2025 | clinicaltrials |
| NCT06524804 | A Phase Ib/II Study of BY101298 , an Oral DNA-PK Inhibitor, Combined with Radiotherapy in Patients with Malignant Solid Tumors | terminated | Phase 1 / Phase 2 | 60 | Chengdu Baiyu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Dec 18, 2024 | clinicaltrials |
| NCT05480865 | SHP2 Inhibitor BBP-398 in Combination With Sotorasib in Patients With Advanced Solid Tumors and a KRAS-G12C Mutation(Argonaut) | terminated | Phase 1 | 28 | Navire Pharma Inc., a BridgeBio companyINDUSTRY | 7 | Dec 12, 2024 | clinicaltrials |
| NCT03922204 | A Study of Bispecific Antibody MCLA-145 in Patients With Advanced or Metastatic Malignancies | completed | Phase 1 | 72 | Merus B.V.INDUSTRY | 4 | Dec 11, 2024 | clinicaltrials |
| NCT04020185 | Safety and Efficacy Study of IMSA101 in Refractory Malignancies | completed | Phase 1 / Phase 2 | 40 | ImmuneSensor Therapeutics Inc.INDUSTRY | 1 | Dec 11, 2024 | clinicaltrials |
| NCT05018273 | Study of VB10.NEO in Combination With Atezolizumab in Solid Tumors | completed | Phase 1 | 26 | Nykode Therapeutics ASAINDUSTRY | 3 | Dec 3, 2024 | clinicaltrials |
| NCT05990920 | Study of Allogeneic Blood-derived Natural Killer Cells to Evaluate Safety and Tolerability in Cancer Refractory to Conventional Therapy | completed | Phase 1 | 6 | NKGen Biotech, Inc.INDUSTRY | 1 | Nov 20, 2024 | clinicaltrials |
| NCT01217411 | RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer | terminated | Phase 1 / Phase 2 | 5 | National Cancer Institute (NCI)NIH | 1 | Nov 19, 2024 | clinicaltrials |
| NCT05228015 | Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects with Advanced Solid Tumors | terminated | Phase 1 | 67 | Ikena OncologyINDUSTRY | 3 | Nov 18, 2024 | clinicaltrials |
| NCT06026254 | A Rollover Study for Subjects Who Completed Participation in IMSA101-101 Trial | active not recruiting | Phase 1 | 2 | ImmuneSensor Therapeutics Inc.INDUSTRY | 1 | Nov 18, 2024 | clinicaltrials |
| NCT06622486 | First-in-human Trial of EGL-001 in Patients with Selected Advanced And/or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 50 | Egle TherapeuticsINDUSTRY | 2 | Nov 7, 2024 | clinicaltrials |
| NCT00483366 | Imatinib Mesylate, Gemcitabine, and Capecitabine in Treating Patients With Advanced Solid Tumors | completed | Phase 1 | 13 | University of NebraskaOTHER | 1 | Sep 23, 2024 | clinicaltrials |
| NCT03516123 | A Study of CS3006 in Subjects with Locally Advanced or Metastatic Solid Tumors | completed | Phase 1 | 18 | CStone PharmaceuticalsINDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT03523819 | A Study of CS1002 in Subjects with Advanced Solid Tumors | completed | Phase 1 | 91 | CStone PharmaceuticalsINDUSTRY | 2 | Sep 19, 2024 | clinicaltrials |
| NCT03873883 | First-in-Human Study of EOS100850 (Inupadenant) in Patients with Cancer(IO-001) | completed | Phase 1 | 119 | iTeos TherapeuticsINDUSTRY | 6 | Sep 19, 2024 | clinicaltrials |
| NCT04474470 | A Study to Evaluate NT219 Alone and in Combination with ERBITUX® (Cetuximab) in Adults with Advanced Solid Tumors and Head and Neck Cancer | completed | Phase 1 / Phase 2 | 52 | TyrNovo Ltd.INDUSTRY | 2 | Sep 19, 2024 | clinicaltrials |
| NCT05117177 | New Formulation Study of Inupadenant (EOS100850) in Patients with Cancer | completed | Phase 1 | 57 | iTeos TherapeuticsINDUSTRY | 2 | Sep 19, 2024 | clinicaltrials |
| NCT06372574 | A Study of RO7617991 in Patients With Locally Advanced or Metastatic MAGE-A4-Positive Solid Tumors | withdrawn | Phase 1 | 0 | Genentech, Inc.INDUSTRY | 0 | Sep 3, 2024 | clinicaltrials |
| NCT00655655 | Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors | completed | Phase 1 | 96 | Mayo ClinicOTHER | 1 | Aug 21, 2024 | clinicaltrials |
| NCT04946864 | A Study to Investigate the Safety, Tolerability, of APG-2575 as a Single Agent or in Combination for Breast Cancer | suspended | Phase 1 / Phase 2 | 65 | Ascentage Pharma Group Inc.INDUSTRY | 2 | Aug 19, 2024 | clinicaltrials |
| NCT03355066 | A Study Evaluating the Safety and Pharmacokinetics of Orally Administered SM08502 in Subjects With Advanced Solid Tumors | terminated | Phase 1 | 82 | Biosplice Therapeutics, Inc.INDUSTRY | 1 | Aug 9, 2024 | clinicaltrials |
| NCT04121442 | Isunakinra Alone and in Combination With a PD-1/PD-L1 Inhibitor in Patients With Solid Tumors | completed | Phase 1 / Phase 2 | 15 | Buzzard PharmaceuticalsINDUSTRY | 1 | Aug 6, 2024 | clinicaltrials |
| NCT06477614 | Anti-cancer DC Cell Vaccination to Treat Solid Tumors | recruiting | Phase 1 | 60 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 27, 2024 | clinicaltrials |
| NCT06195293 | Anti-cancer Neoantigen Polypeptide Vaccine to Treat Solid Tumors | recruiting | Phase 1 | 30 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 26, 2024 | clinicaltrials |
| NCT06195384 | Anti-cancer Neoantigen mRNA Vaccine to Treat Solid Tumors | recruiting | Phase 1 | 30 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 26, 2024 | clinicaltrials |
| NCT06196294 | GPC3/Mesothelin-CAR-γδT Cells Against Cancers | recruiting | Phase 1 | 30 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 26, 2024 | clinicaltrials |
| NCT03778814 | TCR-T Cell Immunotherapy of Lung Cancer and Other Solid Tumors | recruiting | Phase 1 | 30 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 25, 2024 | clinicaltrials |
| NCT04842812 | Engineered TILs/CAR-TILs to Treat Advanced Solid Tumors | recruiting | Phase 1 | 40 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 25, 2024 | clinicaltrials |
| NCT05779917 | Mesothelin/GPC3/GUCY2C-CAR-T Cells Against Cancers | recruiting | Phase 1 | 30 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 25, 2024 | clinicaltrials |
| NCT06473948 | To Assess the Effects of Single Dose of JMKX001899 on QTc Interval in Healthy Subjects | unknown | Phase 1 | 27 | JemincareINDUSTRY | 0 | Jun 25, 2024 | clinicaltrials |
| NCT05054348 | First-in-human Study of IO-108 as Single Agent and in Combination With a PD-1 Immune Check Point Inhibitor in Patients With Advanced Solid Tumors | completed | Phase 1 | 91 | Immune-Onc TherapeuticsINDUSTRY | 1 | Jun 4, 2024 | clinicaltrials |
| NCT05309187 | Dose-Escalation and Dose-Expansion Study of IO-202 and IO-202+Pembrolizumab in Solid Tumors | completed | Phase 1 | 22 | Immune-Onc TherapeuticsINDUSTRY | 1 | Jun 4, 2024 | clinicaltrials |
| NCT06433726 | A Phase l Study of By101921, an Oral PARP7 Inhibitor, in Patients With Advanced Solid Tumors | unknown | Phase 1 | 60 | Chengdu Baiyu Pharmaceutical Co., Ltd.INDUSTRY | 1 | May 30, 2024 | clinicaltrials |
| NCT05605197 | U87 CART in Treatment of Advanced Solid Tumor | unknown | Phase 1 | 12 | Shanghai Unicar-Therapy Bio-medicine Technology Co.,LtdINDUSTRY | 1 | May 28, 2024 | clinicaltrials |
| NCT04092673 | Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies(Zotatifin) | unknown | Phase 1 / Phase 2 | 30 | Effector TherapeuticsINDUSTRY | 1 | May 21, 2024 | clinicaltrials |
| NCT05868174 | Combination of 177Lu-TLX250 and Peposertib in Patients With Carbonic Anhydrase IX -Expressing Solid Tumors | recruiting | Phase 1 | 36 | Telix Pharmaceuticals (Innovations) Pty LimitedINDUSTRY | 1 | May 1, 2024 | clinicaltrials |
| NCT06348290 | Study to Evaluate the Drug-drug Interaction of JMKX001899 in Healthy Subjects | unknown | Phase 1 | 72 | JemincareINDUSTRY | 0 | Apr 4, 2024 | clinicaltrials |
| NCT04901806 | Study of PBI-200 in Subjects With NTRK-Fusion-Positive Solid Tumors | terminated | Phase 1 | 29 | Pyramid BiosciencesINDUSTRY | 11 | Mar 28, 2024 | clinicaltrials |
| NCT04200963 | A Phase 1a/b Study of IK-175 as a Single Agent and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors and Urothelial Carcinoma | completed | Phase 1 | 78 | Ikena OncologyINDUSTRY | 1 | Mar 15, 2024 | clinicaltrials |
| NCT00020371 | BMS-247550 in Treating Patients With Cancers That Have Not Responded to Previous Therapy | completed | Phase 1 | — | National Cancer Institute (NCI)NIH | 1 | Mar 4, 2024 | clinicaltrials |
| NCT06277804 | A Phase I Study of LTC004 Combin With FC in Patients With Advanced/Metastatic Malignancies Tumor | not yet recruiting | Phase 1 | 48 | LetolabINDUSTRY | 0 | Feb 26, 2024 | clinicaltrials |
| NCT04892043 | Study of SQZ-AAC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors | terminated | Phase 1 | 5 | SQZ BiotechnologiesINDUSTRY | 1 | Feb 23, 2024 | clinicaltrials |
| NCT05078593 | A Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of HLX26 Monoclonal Antibody Injection in Patients With Solid Tumor or Lymphoma | completed | Phase 1 | 18 | Shanghai Henlius BiotechINDUSTRY | 1 | Feb 23, 2024 | clinicaltrials |
| NCT05357898 | Study of SQZ-eAPC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors | terminated | Phase 1 / Phase 2 | 20 | SQZ BiotechnologiesINDUSTRY | 1 | Feb 23, 2024 | clinicaltrials |
| NCT06075849 | Phase I Study to Evaluate Safety and Anti-tumor Activity of PB101, an Anti-angiogenic Immunomodulating Agent | unknown | Phase 1 | 30 | Panolos BioscienceINDUSTRY | 1 | Feb 23, 2024 | clinicaltrials |
| NCT03728179 | RACIN in Patients With Advanced TIL-negative Solid Tumors(RACIN) | completed | Phase 1 | 40 | Centre Hospitalier Universitaire VaudoisOTHER | 1 | Feb 20, 2024 | clinicaltrials |
| NCT00930332 | Methadone Hydrochloride as First-Line Therapy in Treating Patients With Chronic Neuropathic Cancer Pain | terminated | Phase 1 | 8 | NCIC Clinical Trials GroupNETWORK | 1 | Feb 12, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Feb 4, 2025source: clinicaltrials